A pharmaceutical liquid composition includes a solution of a physiologically acceptable salt of 4-phenylbutyric acid, which in one embodiment is the sodium salt of 4-phenylbutyric acid, in an aqueous medium at a concentration of at least 1.34 mmol/ml. The aqueous medium includes glycerol; a viscosity enhancing agent, where the viscosity enhancing agent includes a cellulose derivate, and water. The pharmaceutical liquid composition further includes a sweetening agent.

A pharmaceutical liquid composition includes a solution of a physiologically acceptable salt of 4-phenylbutyric acid, which in one embodiment is the sodium salt of 4-phenylbutyric acid, in an aqueous medium at a concentration of at least 1.34 mmol/ml. The aqueous medium includes glycerol; a viscosity enhancing agent, where the viscosity enhancing agent includes a cellulose derivate, and water. The pharmaceutical liquid composition further includes a sweetening agent.

Gastric residence systems for administration of agents, such as drugs, are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; flexible arms for a gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

Gastric residence systems for administration of agents, such as drugs, are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; flexible arms for a gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.

The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.

Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.

Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.

Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

##STR00001##

Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

##STR00001##